Table 3.
Unadjusted comparison of the proportion of patients with zero bleeds between the individualised rFVIIIFc prophylaxis group of A-LONG and the pooled BAY 94-9027 prophylaxis group from PROTECT VIII
| PROTECT VIII regimen | Patients with no bleeds, % | OR (95% CI) | |
|---|---|---|---|
| BAY 94-9027 | rFVIIIFc individualised PHX | rFVIIIFc vs BAY 94-9027 | |
| Q5D | 44.2 | 1.1 (0.5–2.1) | |
| Q7D | 37.2 | 45.3 | 1.4 (0.7–2.9) |
| Twice weekly | 29.2 | 2.0 (0.8–5.2) | |
CI confidence interval, OR odds ratio, PHX prophylaxis, Q5D every 5 days, Q7D every 7 days, rFVIIIFc recombinant factor VIII–Fc fusion protein